54 results about "Primary disease" patented technology

Methods, systems, and apparatus for assessing a state of a comorbidity associated with a primary disease are provided. The methods comprise receiving at least one autonomic index, neurologic index, stress marker index, psychiatric index, endocrine index, adverse effect of therapy index, physical fitness index, or quality of life index of a patient; comparing the at least one index to at least one reference value; and assessing a state of a body system of the patient that is a site of the comorbidity, based on the comparison. A computer readable program storage device encoded with instructions that, when executed by a computer, perform the method described above is also provided. A medical device system capable of implementing the method described above is also provided.

A radiation therapy system optimized for treating extremities such as the breast has unique geometrical features that enable the system to deliver an accurately located prescribed dose to a target volume while eliminating or reducing the collateral dose delivered to the rest of the patient. An optional integral imaging system provides accurate target volume localization for each treatment session. Utilizing the effects of gravity on a prone patient maximizes the separation of a target volume within the breast to adjacent critical structures such as the chest wall, heart and lungs, thereby reducing long term complications not associated with the primary disease. A shielded interface surface between the radiation source and the patient reduces patient dose due to scattered or stray radiation. A shielded enclosure for the radiation sources combined with the shielded interface surface eliminates the need for primary shielding in the room and allows the therapy system to be used in a transportable, mobile facility.

The present invention relates to a method of treatment of cachexia in a subject in need of treatment. More specifically, the present invention relates to the use of retinoid compounds that act on retinoid X receptors (RXRs) for the treatment of cachexia in a subject in need of treatment. The cachexia is associated with, in other words a complication of, a primary disease, condition or disorder. Primary diseases, conditions and disorders include, but are not limited to, cancer, AIDS, liver cirrhosis, diabetes mellitus, chronic renal failure, chronic obstructive pulmonary disease, chronic cardiac failure, immune system diseases (e.g., rheumatoid arthritis and systemic lupus erythematosus), tuberculosis, cystic fibrosis, gastrointestinal disorders (e.g., irritable bowel syndrome and inflammatory bowel disease), Parkinson's disease, anorexia nervosa, dementia, major depression, an aged condition and sarcopenia.

In an attempt to improve primary disease responsiveness and/or to overcome resistant disease, the present disclosure provides a method for treating or inhibiting the proliferation of a WT-1-dependent cancer comprising providing to a subject in need thereof a therapeutically effective amount of a tyrosine kinase inhibitor along with an anti-WT-1/HLA antibody, that is, an antibody that specifically binds to a peptide of Wilms' tumor protein (WT-1) presented on the surface of the cancer cells in an HLA-restricted fashion.

The invention relates to a complication onset risk prediction method and system based on electronic medical record big data, a terminal and a storage medium. The method comprises the steps: collectingelectronic medical record data of the same primary disease crowd, wherein the primary disease crowds comprise primary disease crowds with related complications and primary disease crowds without complications; extracting features related to the complications of the primary disease from the electronic medical record data, and selecting features with significant differences from the extracted features by adopting a normal distribution test; classifying the features with significant differences to form a data set for constructing a model; and constructing a complication onset risk prediction model of the primary disease according to the data set. The method has no side effect on patients, has certain technical intensification, can greatly improve the machine processing speed, improves the working efficiency of doctors, and can save the medical cost.

A Chinese medicine for treating the primary thrombopenic purpura is prepared from 5 Chinese-medicinal materials including natural indigo, forsythia fruit, tree peony bark, liquorice root, etc. Its preparing process is also disclosed.

The invention provides a medical composition for treating headaches and migraine, which is prepared from the following raw drugs by weight: 20-40 parts of concha haliotidis, 20-40 parts of nacre, 20-40 parts of ossa draconis, 20-40 parts of concha ostreae, 12-24 parts of radix paeoniae alba, 8-16 parts of angelica sinensis, 8-16 parts of largehead atractylodes rhizome, 8-16 parts of radix bupleuri, 12-24 parts of tuckahoe, 20-30 parts of uncaria rhynchophylla, 8-16 parts of negundo chastetree fruit, 7-13 parts of chastetree fruit, 7-13 parts of mint, 7-13 parts of ginger and 4-8 parts of liquorice. The invention also provides a preparation method and application of the medical composition. The medical composition provided by the invention can be used for effectively eliminating or greatlyrelieving traditional Chinese medicine syndromes such as hyperaction of liver Yang, liver fire flaming, deficiency of liver-yin and kidney-yin, blood stasis and the like and symptoms of headaches andmigraine caused by various diseases, and curing partial primary diseases of the headaches to a certain extent, therefore, a new approach is provided for the clinical medication.

The invention discloses a penicillium bilaiae capable of preventing sesame blight and promoting and guiding resistance and a screening method and application thereof. The penicillium bilaiae is penicillium bilaiae 47M-1 (Penicillium bilaiae) which is preserved in the China Center for Type Culture Collection, the preservation address is Wuhan University center for Collection, the preservation codeis CTCC M: 2018899, and the preservation data is December 17 , 2018. a strain has strong inhibition effect on sesame fusarium oxysporum, broad-spectrum bacterial inhibiting activity on pathogenicbacteria of other primary diseases of sesame is achieved, the growth of crops can be promoted to guide the crops to generate resistance, the penicillium bilaiae has no pathogenicity on the crops, common problems of chemical pesticides of the resistance to drugs, pesticide residues and environmental pollution are prevented, the penicillium bilaiae is healthy towards human and livestock and friendlyto the environment, and the demands on ecological agriculture of people are conformed.

A disease specific panel having at least one primary test for different analytes that are relevant for either early detection of a primary disease or management of patients already diagnosed with said primary disease. The panel also includes at least one secondary test which is relevant for detection of a co-morbid condition or complications of the primary disease. Generally, the primary and secondary tests are disposed on a support surface. The disease specific panel is different from the prior art creening tests in that there are no tests included in the panel whose results are not relevant or do not relate to either primary disease or a co-morbid condition or complications of the primary disease. The disease specific panel may also include systems and methods utilizing algorithms for creating and outputting diagnostic aids, as well as warnings about the presence of possible sample interferants, especially those commonly associated with the subject disease of the panel.

The invention provides an externally used pharmaceutical composition for treating eruption. The externally used pharmaceutical composition is an externally used preparation prepared by the following active ingredients in parts by weight: 14-26 parts of fructus kochiae, 14-26 parts of fructus cnidii, 14-26 parts of chaulmoogra tree seeds, 14-26 parts of radix sophorae flavescentis, 14-26 parts of smilax glabra, 14-26 parts of cortex dictamni, 8-16 parts of radix lithospermi, and 8-16 parts of herba schizonepetae. The invention further provides a preparation method and applications for the pharmaceutical composition. The pharmaceutical composition can effectively eliminate or greatly relieve the symptoms of eruption diseases such as eczema, prurigo and the like, can eliminate disease source influence of hypersensitivity and the like and heal the primary diseases, and provides a new choice for clinical medicine.

The invention provides a medicine composition for treating rashes. The medicine composition is a preparation prepared from the following active pharmaceutical ingredients in parts by weight: 20-40 parts of lemna minor, 17-31 parts of coix seed, 17-31 parts of rhizoma smilacis glabrae, 10-20 parts of belvedere fruit, 7-13 parts of radix sophorae flavescentis, 7-13 parts of cortex dictamni, 7-13 parts of rhizoma atractylodes, 17-31 parts of flaxseed, 7-13 parts of periostracum cicadae, 2-5 parts of Chinese tamarisk twig, 4-8 parts of fineleaf schizonepeta herb, 4-8 parts of divaricate saposhnikovia root, 5-11 parts of great burdock achene, 17-31 parts of gypsum, 7-13 parts of rhizoma anemarrhenae, 7-13 parts of cortex phellodendri, 10-20 parts of Sinkiang arnebia root, 8-16 parts of radix rehmanniae, 7-13 parts of angelica sinensis and 2-5 parts of liquorice. The invention also provides a preparation method and an application of the medicine composition. The medicine composition can effectively eliminate or greatly relieve the symptoms of such rash diseases as eczema, prurigo and rubella, can cure the primary diseases to some extent and provides a new choice for clinical medication.

An object of the present invention is to provide a drug with a high therapeutic or prophylactic effect on dyskinesia, without accompanying aggravation of symptoms of the primary disease, and with fewer side effects.

Accordingly, the present invention provides a therapeutic or prophylactic agent for dyskinesia, comprising as an effective component a compound having a 4,5-epoxy morphinan skeleton, which compound is represented by the Formula (I) below, or a pharmaceutically acceptable acid addition salt thereof:

[wherein the double line composed of a dashed line and a solid line represents a double bond or single bond, R¹ is C₄-C₇ cycloalkylalkyl, R² is C₁-C₅ straight or branched alkyl, and B is —CH═CH—.]

The invention discloses a life rescue box for first aid of sudden cardiac arrest and acute respiratory failure patients, which is characterized in that main components such as a blood pump, a membrane oxygenator and the like required by extracorporeal life support are assembled in the life rescue box, and the blood pump and the membrane oxygenator are fastened on an upright post in a magnetic force manner; the blood pump is provided with a first interface and a second interface, wherein the first interface is connected with a venous cannula, and the second interface is connected with the membrane oxygenator through a connecting pipe; and the membrane oxygenator is provided with a first interface and a second interface, wherein the first interface is connected with an arterial cannula, and the second interface is connected with the blood pump through a connecting pipe to form a blood circulation loop with the blood vessel of human bodies for alternatively completing the cardio-pulmonary function of the sudden cardiac arrest and acute respiratory failure patients. Due to small size, the life rescue box can be carried with an ambulance and an on-vehicle stretcher, is convenient to move and simple to operate, can reach the primary disease outbreak scene with medical personnel in the shortest time during first aid and can be generally used for the first aid of the sudden cardiac arrest and acute respiratory failure patients.

The invention relates to a rapid disease detection and information acquisition method. The color development degree of a disease marker sample in an immunochromatographic detection system is converted into data, the data are saved to form a saved file, and the file is input to a specified server through network by using mobile communication terminal equipment as an intermediate. The method facilitates the primary disease diagnosis and the database establishment of medical and detection organizations.

The invention relates to a disease code conversion method, which comprises the following steps of S01, acquiring the code versions corresponding to the standard disease codes and the standard diagnosis descriptions, and establishing a standard dictionary library; S02, establishing a test set according to disease codes needing to be converted and the diagnosis description; S03, forming term vectorsaccording to the standard dictionary library and the test set; S04, extracting the front N-bit coded values of the disease codes needing to be converted, and obtaining the primary disease codes; S05,for the term vector, calculating a similarity value, and obtaining the primary disease code of the specific version corresponding to the maximum similarity value; and S06, according to clinical rules, verifying the mapping relation between the obtained primary disease code of the specific version and the disease code needing to be converted, and determining the converted disease code. The methodhas the beneficial effects that the accuracy of the converted disease codes is ensured, and the conversion among various versions of disease codes is realized.

The invention discloses a Chinese herbal medicine compound preparation for curing endometriosis and pelvic pain of the endometriosis. The preparation comprises, by weight, 3-20 parts of Chinese honey locust spines, 3-20 parts of zedoray rhizomes, 3-20 parts of chinaberry fruits, 4-30 parts of corydalis tuber, 6-40 parts of giant knotweeds and 2-12 parts of arum. The preparation is fed through rectums, the pain relief effect is quick, the curative effect is good, no side effect exists, and preparation can replace steroid analgesics, nonsteroidal analgesics and hormone analgesics and can cure primary disease if being used for a long time. The invention also relates to medical application of the Chinese herbal medicine compound preparation.

The invention discloses a molecular marker DNdCAPS8.03-1 chained with corn head smut-resistant secondary and primary loci and application thereof, and belongs to the technical field of gene engineering. The invention further relates to an SNP (Single Nucleotide Polymorphism) locus chained with the corn head smut-resistant secondary and primary loci. The SNP locus is positioned at the 3169th site in a resistance gene candidate GRMZM2G047152 open reading frame in a corn genome bin8.03 area; when the locus is G, disease resistance is shown; when the locus is A, disease infection is shown. A dCAPS marker is developed based on an SNP marker, and is named as DNdCAPS8.03-1; an incision enzyme of the molecular marker is BsiHKAI; a restriction enzyme cutting site is GWGCWC; a PCR amplification product is 137bp; a product after enzyme digestion is 114bp. When the DNdCAPS8.03-1 is used in combination with molecular markers MZA6393 and LSdCAP2 which are positioned in a bin2.09 primary disease-resistant locus area, the selection efficiency is greatly higher than that of a single marker. Thus, the molecular marker NdCAPS8.03-1 can be applied to corn head smut-resistant molecular marker-assisted breeding, so that the selection process of screened disease-resistant varieties of corn head smut-resistant germplasm resources is accelerated.

In an attempt to improve primary disease responsiveness and/or to overcome resistant disease, the present disclosure provides a method for treating or inhibiting the proliferation of a WT-1 -dependent cancer comprising providing to a subject in need thereof a therapeutically effective amount of a tyrosine kinase inhibitor along with an anti-WT-1 /HLA antibody, that is, an antibody that specifically binds to a peptide of Wilms' tumor protein (WT-1 ) presented on the surface of the cancer cells in an HLA-restricted fashion.

The invention provides a statin-associated myopathy detecting device. The device performs Massarray SNP genotyping detection in accordance with a single nucleotide polymorphism site rs976754 of a sample to be detected. The device comprises the following composition mechanisms of a primer synthesizing mechanism, a sample detection quantifying mechanism, a PCR reaction mechanism, a single-base extension reaction mechanism and a computer detection and analysis mechanism. The genotype at the site has important directive significance in recognizing myopathy high-risk crowds and adjusting medicationat the early stage, and has important significance in screening myopathy risk genes at the early stage, forecasting the myopathy generation risk, providing individualized medication guidance, reducing the generation of adverse drug reactions, performing prognosis and outcome of primary diseases, and improving the life quality of patients needing to take statin type blood lipid reducing medicines.

The invention discloses a natto sauce containing a compound phytosterol-curcumin self-microemulsion and a preparation method thereof. The natto sauce containing the compound phytosterol-curcumin self-microemulsion comprises the following raw materials by weight: 120 to 180 parts of soybeans, 5 to 10 parts of the compound phytosterol-curcumin self-microemulsion, 10 to 30 parts of other crops, 0.05to 0.15 part of Bacillus natto powder, 0.5 to 1.5 parts of garlic, 1 to 2 parts of egg white, 0.8 to 1.2 parts of edible vinegar, 0.5 to 1 part of onions, 1 to 2 parts of plant oil, 1 to 2 parts of salt, 0.5 to 1 part of capsicum, 0.5 to 1 part of soy and 0.4 to 0.8 part of sugar. According to the invention, the obtained compound phytosterol-curcumin self-microemulsion has a particle size of lessthan 60 nm, a phytosterol loading amount of more than 8.26 mg/g, a curcumin loading amount of more than 0.64 mg/g and an entrapment rate of more than 90%; and phytosterol and curcumin have different hypolipidemic mechanisms and complement each other to achieve cooperative hypolipidemic efficacy. The above natural nontoxic substances with obvious hypolipidemic functions are compounded in the invention, so the natto sauce can prevent and mitigate cardiovascular diseases with hyperlipidemia as a primary disease and has good health care effect.

The invention provides an external-use medicine composition for treating eruption and a preparation method and application of the composition. An external-use medicine composition is prepared from the following raw medicines in parts by weight: 14 to 26 parts of pollen typhae, 7 to 13 parts of lithargite, 7 to 13 parts of dried alum, 7 to 13 parts of golden cypress and 3 to 7 parts of ice sheet. The invention also provides a preparation method and application of the medicine composition. The medicine composition can effectively eliminate or greatly relieve symptoms of eruption diseases such as eczema and prurigo by an external treatment method and can eliminate influence of a source of the disease caused by hypersensitivity to a certain extent; the primary disease can be treated; and a new selection is supplied to clinical medicine use.

A Hypericum Japonicum Thunb electuary for eliminating stasis to subdue swelling is prepared from the following raw materials (by weight): 35-45 parts of Hypericum Japonicum Thunb, 15-25 parts of Daphne odora leaf, 15-25 parts of red sage root, 10-15 parts of whole plant of Pygmaeopremna herbacea (Roxb.) Moldenke, 10-15 parts of curcuma tuber, 10-15 parts of Root and leaf of Rosthorn Bigginseng, 10-15 parts of corydalis tuber, 5-10 parts of Yunnan dutchmanspipe rhizome, 5-10 parts of mulberry bark, 5-10 parts of Strychnos nuxvomica, 5-10 parts of Herba Cladostachvdis, 5-10 parts of fortune euonymus, 4-8 parts of rock sugar, 4-8 parts of brown sugar, 4-8 parts of resistant dextrin and 4-8 parts of sorbitol. The preparation method comprises the following main steps: Step 1, pretreatment of raw materials; Step 2, crushing and mixing; Step 3, decoction and cooling; Step 4, filtration, extraction and concentration; Step 5, drying and crushing; and Step 6, sterilization and bagging. The Hypericum Japonicum Thunb electuary for eliminating stasis to subdue swelling has effects of eliminating stasis to subdue swelling, supporting right and securing the root, invigorating blood circulation and relieving pain on primary diseases and symptoms such as rheumatism, obstinate arlhralgia, numbness, paralysis, etc.